Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 11, 1998, Pages 598-606

  Kolkhorst, Valentina ^a   Stürzebecher, Jörg ^a   Wiederanders, Bernd ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Inhibition of invasion; Matrigel assay; Protease inhibitors; Protease profile

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; BATIMASTAT; CATHEPSIN B; CATHEPSIN L; ENZYME INHIBITOR; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; THROMBIN INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; TUMOR CELL;

CATHEPSIN B; CATHEPSINS; CELL MOVEMENT; COLLAGEN; COLLAGENASES; CULTURE MEDIA; CYSTEINE ENDOPEPTIDASES; DRUG COMBINATIONS; ENDOPEPTIDASES; GELATINASES; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PROTEASE INHIBITORS; PROTEOGLYCANS; TUMOR CELLS, CULTURED;

EID: 0031774869     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050221     Document Type: Article

References (53)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Auronson SA, Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245
2. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM (1997) Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405:157-162
3. Barrett AJ (1995) Proteolylic enzymes: aspartic and metallo peptidases. Methods Enzymol 248
4. Barrett AJ, Kirschke H (1981) Cathepsin B, cathepsin H, and cathepsin L. Methods Enymol 80:535-561
5. Bepler G, Jaques G, Koehler A, Gropp C, Havemann K (1987) Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol 113:253-259
6. Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, Haeder M (1988) Characterization of the state of differentiation of six newly established human nonsmall cell lung cancer cell lines. Differentiation 37:158-171
7. Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D, Rochefort H (1991) MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 194:252-259
8. Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Ocol 6:967-974
9. Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M (1998) In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 75:418-431
10. Fødstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A (1988) A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 41:442-4499
11. Gilles C, Polette M, Piette J, Delvigne AC, Thompson EW, Foidart JM, Birembaut P (1996) Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 180:175-180
12. Hiscox S, Jiang WG (1997) Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Res 17:1349-1354
13. Kirschke H, Wood L, Roisen FJ, Bird JW (1983) Activity of lysosomal cysteine proteinase during differentiation of rat skeletal muscle. Biochem J 214:871-877
14. Kirschke H, Wiederanders B, Bromme D, Rinne A (1989) Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J 264:467-473
15. Kobayashi Y, Staquet MJ, Dezutter Dambuyant C, Schmitt D (1995) In vitro migration capacity of epidermal Langerhans cells. Adv Exp Med Biol 378:169-171
16. Kolár Z, Dufek V, Krepela E, Vicar J, Kral V (1985) Changes in tissue and serum activity of cathepsin B-like cysteine proteinase during colorectal carcinogenesis by 1,2-dimethylhydrazine in mice. Neoplasma 32:571-579
17. Lenarcic B, Krasovec M, Ritonja A, Olafsson I, Turk V (1991) Inactivation of human cystatin C and kininogen by human cathepsin D. FEBS Lett 280:211-215
18. Leto G, Pizzolanti G, Tumminello FM, Gebbia N (1994) Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In vivo 8:231-236
19. Liotta LA, Steeg PS, Stetler Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336
20. Littlewood Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans DB, Gallagher JA (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386-5390
21. Mach L, Schwihla H, Stuwe K, Rowan AD, Mort JS, Glossl J (1993) Activation of procathepsin B in human hepatoma cells: the conversion into the mature enzyme relies on the action of cathepsin B itself. Biochem J 293:437-442
22. Mackay AR, Gomez DE, Cottam DW, Rees RC, Nason AM, Thorgeirsson UP (1993) Identification of the 72-kDa (MMP-2) and 92-kDa (MMP-9) gelatinase/type IV collagenase in preparations of laminin and matrigel. Bio techniques 15:1048-1051
23. Macready N (1997) Protease inhibitors. Novel therapeutic application and development. International business communications, Southborough, Mass
24. Maubach G, Schilling K, Rommerskirch W, Wenz I, Schultz JE, Weber E, Wiederanders B (1997) The inhibition of cathepsins by its propeptide. Specificity and mechanism of action. Eur. J. Biochem 250:745-750
25. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332
26. McGuire PG, Orkin RW (1987) Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 57:94-105
27. Menard R, Carmona E, Takebe S, Dufour E, Plouffe C, Manson P, Mort JS (1998) Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro. J Biol Chem 273:4478-4484
28. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195
29. Mignatti P, Rifkin DB (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137
30. Mooradian DL, McCarthy JB, Komanduri KV, Furcht LT (1992) Effects of transforming growth factor-beta 1 on human pulmonary adenocarcinoma cell adhesion, motility, and invasion in vitro. J Natl Cancer Inst 84:523-527
31. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT (1997) Transmembrane cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 94:7959-7964
32. Niedbala MJ, Picarella MS (1992) Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood 79:678-687
33. Nishimura Y, Kato K (1987) Intracellular transport and processing of lysosomal cathepsin H. Biochem Biophys Res Commun 148:329-334
34. Nishimura Y, Furuno K, Kato K (1988) Biosynthesis and processing of lysosomal cathepsin L in primary cultures of rat hepatocytes. Arch Biochem Biophys 263:107-116
35. Noel AC, Callé A, Emonard HP, Nusgens BV, Simar L, Foidart J, Lapiere CM, Foidart J-M (1991) Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Res 51:405-414
36. Nomura H, Sato H, Seiki M, Mai M, Okada Y (1995) Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55:3263-3266
37. Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valentine T, Swarm R (1977) A murine tumor producing a matrix of basement membrane. J Exp Med 145:204-220
38. Parsons SL, Watson SA, Steele RJ (1997) Phase I II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23:526-531
39. Pintucci G, Iacoviello L, Castelli MP, Amore C, Evangelista V, Cerletti C, Donati MB (1993) Cathepsin G-induced release of PAI 1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear leukocytes? J Lab Clin Med 122:69-79
40. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, Tournier JM, Birembaut P (1996) MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428:29-35
41. Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75: 69-75
42. Redwood SM, Liu BCS, Weiss RE, Hodge DE, Droller MJ (1992) Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69:212-219
43. Seftor RE, Seftor EA, Cress AE, Hendrix MJ (1990) Profiles of human melanoma cell surface proteins: effects of culturing on two different substrates. Pigment Cell Res 3:44-48
44. Scaddan PB, Dufresne MJ (1993) Characterization of cysteine proteases and their endogenous inhibitors in MCF-7 and adriamycin-resistant MCF-7 human breast cancer cells. Inv Metast 13:301-313
45. Sinha AA, Wilson MJ, Gleason DF, Reddi PK, Sameni M, Sloane BF (1995) Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26:171-178
46. Solovyeva NI, Balayevskaya TO, Dilakyan EA, Zakamaldina-Zama TA, Poznev VF, Totol LZ (1995) Proteolytic enzymes at various stages of oncogenic transformation of rat fibroblasts. I. Aspartyl and cysteine proteinases. Int J Cancer 60:495-500
47. Stürzebecher J, Prasa D, Hauptmann J, Wikström P, Vieweg H (1995) Structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J Enzym Inhib 9:87-99
48. Stürzebecher J, Prasa D, Hauphmann J, Wikström P, Vieweg H (1997) Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidino-phenylalanine. J Med Chem 40:3091-3099
49. Thorgeirsson UP, Mackay AR (1993) Characterization of metastatic tumour cells. In: Tumour immunobiology. A practical approach. (Gallagher G, Rees RC, Reynolds CM eds) Oxford University Press Oxford, New York, Tokyo 399-412
50. Vukicevic S, Kleinman HK, Luyten FP, Roberts AB, Röche NS, Reddi H (1992) Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 202:1-8
51. Wiederanders B, Kirschke H (1989) The processing of a cathepsin L precursor in vitro. Arch Biochem Biophvs 272:516-521
52. Wilhelm O, Reuning U, Jänicke F, Schmitt M, Graeff H (1994) The role of proteases in tumor invasion and metastasis: prognostic impact and therapeutical challenge? Onkologie 17:358-366
53. Wojtowicz Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75